Your browser doesn't support javascript.
loading
High mobility group box 1 is increased in the sera of psoriatic patients with disease progression.
Bergmann, C; Strohbuecker, L; Lotfi, R; Sucker, A; Joosten, I; Koenen, H; Körber, A.
Afiliación
  • Bergmann C; Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany.
  • Strohbuecker L; Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Lotfi R; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
  • Sucker A; Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Joosten I; Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Koenen H; Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Körber A; Department of Dermatology, University Hospital Essen, Essen, Germany.
J Eur Acad Dermatol Venereol ; 30(3): 435-41, 2016 Mar.
Article en En | MEDLINE | ID: mdl-26834049
BACKGROUND: Psoriasis vulgaris (PV) is an autoimmune-related chronic inflammatory disease, which appears mostly in skin, but also affects the vascular and metabolic system. The incidence of PV is 2-3% in the general population and there is still no possibility to cure. Trigger factors have been identified to initiate and maintain inflammation in the skin, which is characterized by Th1-, Th17- and Th22- cells. OBJECTIVE: We hypothesize that the damage-associated molecular pattern (DAMP) molecule high mobility group box 1 (HMGB1) plays a role in the pathogenesis of PV. HMGB1 is a DNA-binding protein located in the nucleus, which acquires cytokine-like properties once released from the cell upon necrotic cell death or actively secreted by immune cells in inflammation and cancer. METHODS: We recruited 90 psoriatic patients under and without therapy with mild, intermediate and severe progression of disease, defined by the Psoriasis Area Severity Index. Serum levels of HMGB1 in patients with PV were detected by enzyme-linked immunosorbent assay (ELISA). RESULTS: Our results show an increased level of HMGB1 in the sera of patients with PV in comparison to healthy donors. Furthermore, our analyses reveal that HMGB1 levels are significantly increased with disease progression and are downregulated after standard therapies for PV have been conducted. CONCLUSION: Our data provide insights into a possible role of HMGB1 for inflammation in PV.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Piel / Proteína HMGB1 Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Piel / Proteína HMGB1 Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido